Disclaimers

This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payors for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
## About InspireMD

InspireMD is a commercial-stage medical device company focused on stroke prevention for patients with carotid artery disease and other vascular diseases utilizing an integrated embolic protection technology.

### COMPANY

<table>
<thead>
<tr>
<th>NYSE AMER:</th>
<th>NSPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employees:</td>
<td>46</td>
</tr>
<tr>
<td>Headquarters:</td>
<td>Tel Aviv</td>
</tr>
<tr>
<td>Manufacturing Facility:</td>
<td>Tel Aviv</td>
</tr>
<tr>
<td>Commercial and Clinical Employees:</td>
<td>Germany, UK, Spain, Israel</td>
</tr>
</tbody>
</table>

### TECHNOLOGY

- Proprietary MicroNet™ technology

### PRODUCTS

**Commercial:**
- CGuard™ EPS (Carotid)
- MGuard™ EPS (Coronary)

**Pipeline:**
- CGuard™ EPS USA
- Next Gen CGuard™
- PVGuard™ (Peripheral)
- NGuard™ (Neuro)
## Company Highlights

### CGuard™ EPS

- **Enabling a paradigm shift (CAS)** in the treatment of carotid artery disease and stroke prevention
- **Breakthrough platform**: Highly differentiated, with strong support from leading clinicians
- **MicroNet™ technology** that is elegantly simple, propriety and easily leveraged to other medical devices

### Benefits demonstrated in multiple trials

- **Clinical Evidence / Data Driven**: 7 completed and 4 ongoing clinical trials
- **Differentiation** versus conventional carotid stents and surgery
- **Outcomes based**: No device related major adverse events. No major strokes
- **Sustainable results**: Long term benefit reported in all-comer population

### Commercial Growth

- **Expanding Existing Footprint**: Deeper penetration within key markets
- **Results**: 2018 CGuard™ EPS sales increased 55% YoY
- **Commercial Model Development**: Evaluating opportunities to go direct in key markets

### 1B Global Market Opportunity

- **Expansion into OUS Markets**: Near Term: Brazil; Strategic Partners Discussions in Japan and China
- **United States**:
  - IDE FDA submission for CGuard™ EPS July 2019
  - Additional request from FDA for information in support of application August 2019
  - Working closely with FDA to resolve additional requests for information
  - Critical step in commencing human trial in the USA

### Capital Structure

- **Recapitalized** the company to clean up the capital structure and prepare for growth
- **Capital use** focused on commercial execution, IDE and pipeline

### Pipeline and Strategic Opportunities

- **Leverage** MicroNet™ into other pipeline opportunities in neurovascular and peripheral vascular diseases
- **Proactively** seek synergistic product opportunities
- **Add** BD resources to effectively assess inbound queries and implement a more focused and proactive BD strategy.
Stroke is the Second Biggest Cause of Death
An estimated 15 million people suffer from stroke annually

- 6.2 million deaths
- 5 million people left permanently disabled
- $34 billion associated with stroke management in the US alone
- ~ 85% of all strokes are ischemic strokes, which result from a lack of blood flow to the brain
- Carotid artery disease (CAD) is a major risk factor for stroke
- Approximately 20% of all ischemic strokes are estimated to be caused by CAD (2.2-2.4 million)

1 https://www.worldstrokecampaign.org/learn/facts-and-figures.html
2 Center For Disease Control and Prevention – Stroke Facts – 2017
3 http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html
4 State of the Nation Stroke statistics - January 2016
6 https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Unmet Need: A Safer Technology for Stroke Prevention in CAD
Surgery vs. Carotid Artery Stenting

Carotid Endarterectomy (CEA)

“Gold standard”¹, but...
Invasive; risk of surgical complications
• Myocardial Infarction¹
• Risk of cranial nerve injury²
• Esthetic concern

Filter Protected Stenting (CAS)

Patient friendly, long-term durability¹,
Non-Invasive; risk of complications
• Procedural minor stroke risk (with conventional stents)¹
• Post-procedural minor stroke risk (with conventional stents)¹

Based on the CREST clinical trial data, in which only conventional carotid stents were used vs. surgery

¹CREST Trial: N Engl J Med 2010;363:11-23
²Circulation. 2012;125:2256-2264
Current Treatments for Carotid Artery Disease
Surgery (Carotid Endاردurectomy) (CEA) vs. Conventional Carotid Stents (CAS)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>no. of patients</td>
<td></td>
<td>Absolute Treatment Effect of CAS vs. CEA (95% CI)</td>
<td>Hazard Ratio for CAS vs. CEA (95% CI)</td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td>percentage points</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td>0.4 (−0.2 to 1.0)</td>
<td>2.25 (0.69 to 7.30)†</td>
</tr>
<tr>
<td>Any</td>
<td>9 (0.7±0.2)</td>
<td>4 (0.3±0.2)</td>
<td>1.8 (0.4 to 3.2)</td>
<td>1.79 (1.14 to 2.82)</td>
</tr>
<tr>
<td>Major ipsilateral</td>
<td>52 (4.1±0.6)</td>
<td>29 (2.3±0.4)</td>
<td>0.5 (−0.1 to 1.2)</td>
<td>2.67 (0.85 to 8.40)</td>
</tr>
<tr>
<td>Major nonipsilateral</td>
<td>0</td>
<td>4 (0.3±0.2)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Minor ipsilateral</td>
<td>37 (2.9±0.5)</td>
<td>17 (1.4±0.3)</td>
<td>1.6 (0.4 to 2.7)</td>
<td>2.16 (1.22 to 3.83)</td>
</tr>
<tr>
<td>Minor nonipsilateral</td>
<td>4 (0.3±0.2)</td>
<td>4 (0.3±0.2)</td>
<td>0.0 (−0.4 to 0.4)</td>
<td>1.02 (0.25 to 4.07)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>14 (1.1±0.3)</td>
<td>28 (2.3±0.4)</td>
<td>−1.1 (−2.2 to −0.1)</td>
<td>0.50 (0.26 to 0.94)</td>
</tr>
<tr>
<td>Any periprocedural stroke or postprocedural ipsilateral stroke</td>
<td>52 (4.1±0.6)</td>
<td>29 (2.3±0.4)</td>
<td>1.8 (0.4 to 3.2)</td>
<td>1.79 (1.14 to 2.82)</td>
</tr>
<tr>
<td>Major stroke</td>
<td>11 (0.9±0.3)</td>
<td>8 (0.6±0.2)</td>
<td>0.2 (−0.5 to 0.9)</td>
<td>1.35 (0.54 to 3.36)</td>
</tr>
<tr>
<td>Minor stroke</td>
<td>41 (3.2±0.5)</td>
<td>21 (1.7±0.4)</td>
<td>1.6 (0.3 to 2.8)</td>
<td>1.95 (1.15 to 3.30)</td>
</tr>
<tr>
<td>Any periprocedural stroke or death or postprocedural ipsilateral stroke</td>
<td>55 (4.4±0.6)</td>
<td>29 (2.3±0.4)</td>
<td>2.0 (0.6 to 3.4)</td>
<td>1.90 (1.21 to 2.98)</td>
</tr>
<tr>
<td>Primary end point (any periprocedural stroke, myocardial infarction, or death or postprocedural ipsilateral stroke)</td>
<td>66 (5.2±0.6)</td>
<td>56 (4.5±0.6)</td>
<td>0.7 (−1.0 to 2.4)</td>
<td>1.18 (0.82 to 1.68)</td>
</tr>
</tbody>
</table>

Embolization Following Carotid Artery Stenting

Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents, depending on plaque morphology/symptomatic status and stent type. The consequence is cerebral embolization, either directly or via additional thrombus formation.

2/3 of CAS neurovascular events (stroke, TIA) are POST-procedural.**
Consequences Range from Neurological Deficit to Stroke

Pre-Procedure

Pre-intervention showing 90% occlusion of the carotid artery and an MRI showing an old white matter infarction (obstruction).

Post-Procedure

Post-intervention showing successful opening of the occluded carotid artery with conventional stenting and an MRI showing multiple micro-infarcts (obstructions) post-procedure due to liberation of embolic particles.
A Billion Dollar Market Opportunity

- 2.2M diagnosed with carotid artery disease
- 2017: ~600,000 patients with high grade carotid stenosis (HGCS) require interventions for CAD
- At present, ~80% are surgically treated with carotid endarterectomy (CEA)
- At a price of $1,650 per stent, the addressable market is estimated to be more than $1 billion

Carotid procedures today are primarily surgical

Carotid procedures tomorrow could be mostly minimally invasive with CGuard™

MicroNet™ covered stents could become the Gold Standard
**The InspireMD Solution: CGuard™ EPS**

<table>
<thead>
<tr>
<th>Conventional Carotid Stent</th>
<th>CGuard™ EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Plaque protrusion" /></td>
<td><img src="image2" alt="CGuard™ EPS" /></td>
</tr>
</tbody>
</table>

**CGuard™ EPS has been shown to prevent embolic debris passing into the carotid artery and traveling to the brain**

- Carotid plaque can protrude through the stent struts
- The MicroNet™ permanently covers plaque and stops “debris” from passing through the mesh.
- Ultrathin PET mesh made of a single 20 micron fibre from a biocompatible polymer - widely used in other medical implants
- MicroNet™ acts as a “safety net” with greater vessel area coverage to prevent plaque protrusion through the stent into the blood vessel
The InspireMD Solution: CGuard™ EPS

Conventional Carotid Stents

No plaque coverage - leading to plaque protrusions or prolapse passing into the vessel lumen

CGuard™ EPS

The MicroNet™ permanently covers plaque and prevents “debris” from passing through the mesh.

2. Umemoto. et.al. Eurointervention 192 2017
**Positive CGuard™ EPS Clinical Experience**

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Patient Safety and Efficacy clinical trial</td>
<td>402 patients, 436 devices ongoing registry evaluating CGuard EPS in unselected, consecutive carotid patients (all-comers)</td>
</tr>
<tr>
<td><strong>Zero major adverse cardiac or cerebral events (MACCE) at 30 days</strong> (Comparative data 5.72%*)</td>
<td>99.1% device success in PARADIGM 101</td>
</tr>
<tr>
<td>50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical non-mesh carotid artery stenting data</td>
<td>0% major stroke @ 30 days (0-402)</td>
</tr>
<tr>
<td>All new ischemic lesions fully resolved at 30 days except one</td>
<td>&lt;1% any stroke (minor), death or myocardial infarction (4/402)</td>
</tr>
<tr>
<td>3.6% MACCE rate at 6 months (Comparative data 8.09%**)</td>
<td>0 strokes from 30 days to 1 year (n=311)</td>
</tr>
<tr>
<td>Zero strokes or stroke related deaths at 12 months</td>
<td>0 ipsilateral (device related) strokes from 30 days to 2 years (n=205)</td>
</tr>
</tbody>
</table>

*Trials included in analysis: ARChER pooled, ARMOUR, BEACH, CABERNET, CREATE, EMPIRE, EPIC, MAVERIC 1+2, MAVERIC International, PRIAMUS, SAPPHIRE, SECURITY, PROFI, ICSS

**Values extrapolated from event curves

***Musialek, Presentation at the 2019 Joint Congress of the World Heart Federation and the European Society of Cardiology, Paris FR

"CGuard can safely be used on more than 90% of all-comer patients that have carotid artery stenosis."

- P. Musialek, MD

---

"CGuard can safely be used on more than 90% of all-comer patients that have carotid artery stenosis."

- P. Musialek, MD
Analysis of Published Carotid Stent Trial Data

Comparative analysis of the carotid stent data available in public domains (journal publications plus congress presentations published on-line)

Cumulative Incidence of Death/Stroke/MI @ 30 days plus 1-year ipsilateral stroke rate

Conventional single-layer stents

Combined data from different studies/populations confounders may contribute => compare with caution
Analysis of Published Next Generation Carotid Device Trial Data*

**Patient-level meta-analysis**
556 patients / 4 trials
(both symptomatic and asymptomatic)**

**Dual-layer stents**
1-year data

Cumulative results at one year according to Stent Platform

- Stroke: p = 0.97
- Death: p = 0.12
- Stroke + Death: p = 0.25
- Restenosis: p = 0.003
- In-stent thrombosis
- Restenosis + in-stent: p = 0.007

*Stabile et. al. 1-year results, J. Cardio. Surg. (submitted)
CGuard™ EPS vs Conventional Stents and Surgery

- CGuard™ EPS has a superior profile versus historical data on both conventional carotid stents and surgery
- CGuard™ is a next-generation stent supported by a strong and growing body of clinical data
- 7 completed clinical trials and 4 ongoing trials

30 day MACCE results (Major and Minor Adverse Cardiac and Cerebral Events)

<table>
<thead>
<tr>
<th></th>
<th>CGuard™</th>
<th>Conventional stents</th>
<th>CEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 day MACCE</td>
<td>0.76% (1,2)</td>
<td>5.20% (3)</td>
<td>4.50% (3)</td>
</tr>
</tbody>
</table>

*NOTE: IRRON-GUARD, Wisggott and Casana trials are not included in this calculation of the CGuard data as these trials were not independently monitored

“The CGuard™, in comparison to other [carotid] stents, even in comparison to other mesh covered stents, is a very easy to use device. Very simple, you take it off the shelf and you use it and that’s it.”

“Patient risks associated with stenting using CGuard™ are far lower than those associated with CEA or with other types of carotid stents.

“CGuard™ will become a major factor in preventing strokes caused by carotid artery disease.”

“With CGuard™ we can get excellent results, probably better than open surgery, the Gold Standard”
Commercial Strategy

Transition current users of carotid stents to CGuard™ EPS
Continued communication of CGuard™ EPS clinical data
Continue to support investigator initiated clinical registries
Continue to develop network of KOLs, broaden centers of excellence to multiple clinical disciplines

Transition Vascular Surgeons to CGuard™
Advisory boards, surgeon specific clinical registries, centers of excellence
Publish, present, and communicate data demonstrating that CGuard™ is as safe as CEA
Establish a presence at major vascular surgery meetings
Expand digital, social and other tools to more effectively communicate

Expand footprint in existing geographical areas
Focus limited resources on larger markets with highest opportunities – Germany, Italy, Spain, Poland
Support regional clinical and clinical specialty registries to build on the clinical database and broaden support
Evaluating further market growth via direct sales in key regional markets

Continue geographical expansion where strategically relevant
Ongoing discussions with partners to bring CGuard To Japan and China
Obtain US IDE approval
CGuard™ EPS Product Development

US FDA
- IDE FDA submission for CGuard™ EPS July 2019
- Additional request from FDA for information in support of application August 2019
- Working closely with FDA to resolve additional requests for information
- Critical step in commencing human trial in the USA

Innovative Pipeline Developments
- CGuard continuous improvements (including COGS)
- Peripheral vascular products
- Neurovascular

Evaluating external opportunities
- Proactively evaluating synergistic opportunities to further broaden the product portfolio and take advantage of the global distribution network that has been developed
- Add BD resources to effectively assess inbound queries and implement a more focused and proactive BD strategy
Addressable Stroke Prevention Device Market

- 13mn people globally with high grade carotid stenosis (HGS)
- 2.2mn people with HGS diagnosed
- ~600,000 received surgical/stent treatment
- Untapped market: At least 1.6mn patients could be helped by CGuard EPS
- Plus roughly 10mn people who are undiagnosed

2017: ~600,000 patients with high grade carotid stenosis (HGS) require interventions for CAD. At present, ~80% are surgically treated with carotid endarterectomy (CEA)

The balance are treated with conventional carotid stents (CAS) with an average of 1.05 stents/procedure

At a price of $1,650 per stent, the addressable market is estimated to be more than $1 billion
Intellectual Property Portfolio

<table>
<thead>
<tr>
<th>PATENT RIGHTS</th>
<th>ISSUED</th>
<th>ALLOWED</th>
<th>PENDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>13</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Rest of World</td>
<td>47</td>
<td>0</td>
<td>19</td>
</tr>
</tbody>
</table>

Proprietary platform technology supported by a robust intellectual property portfolio

Continue to strengthen and broaden patent protection globally to enable future pipeline products
## Leadership

Significant track records of success

<table>
<thead>
<tr>
<th>Name</th>
<th>Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Barry, Ph.D.</td>
<td><img src="image" alt="Boston Scientific" /></td>
</tr>
<tr>
<td>President and CEO</td>
<td><img src="image" alt="Pfizer" /></td>
</tr>
<tr>
<td>Craig Shore</td>
<td><img src="image" alt="Pfizer" /></td>
</tr>
<tr>
<td>CFO</td>
<td><img src="image" alt="Boston Scientific" /></td>
</tr>
<tr>
<td>Paul Stuka</td>
<td><img src="image" alt="Osiris" /></td>
</tr>
<tr>
<td>Chairman</td>
<td><img src="image" alt="Fidelity" /></td>
</tr>
<tr>
<td>Michael Berman</td>
<td><img src="image" alt="Boston Scientific" /></td>
</tr>
<tr>
<td>Director</td>
<td><img src="image" alt="Veloximed™" /></td>
</tr>
<tr>
<td>Campbell Rogers, M.D.</td>
<td><img src="image" alt="LUTONIX" /></td>
</tr>
<tr>
<td>Director</td>
<td><img src="image" alt="Harvard Medical School" /></td>
</tr>
<tr>
<td>Thomas Kester</td>
<td><img src="image" alt="Kester Search Group®" /></td>
</tr>
<tr>
<td>Director</td>
<td><img src="image" alt="KPMG" /></td>
</tr>
<tr>
<td>Sol Barer, Ph.D.</td>
<td><img src="image" alt="Celgene" /></td>
</tr>
<tr>
<td>Special Advisor to the Board</td>
<td><img src="image" alt="TEVA" /></td>
</tr>
</tbody>
</table>
## Summary Financials

<table>
<thead>
<tr>
<th>NYSE AMERICAN</th>
<th>NSPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price (10/31/19):</td>
<td>$1.13</td>
</tr>
<tr>
<td>Average last month daily trading volume:</td>
<td>242 K</td>
</tr>
<tr>
<td>Shares outstanding (10/31/19):</td>
<td>3.6 M</td>
</tr>
<tr>
<td>Shares outstanding including full conversion of</td>
<td></td>
</tr>
<tr>
<td>preferred shares and prefunded warrants (10/31/19):</td>
<td>4.9 M</td>
</tr>
<tr>
<td>Market capitalization including full conversion of</td>
<td></td>
</tr>
<tr>
<td>preferred shares and prefunded warrants (10/31/19):</td>
<td>$5.5 M</td>
</tr>
<tr>
<td>Cash (9/30/19):</td>
<td>$7.2 M</td>
</tr>
</tbody>
</table>
Summary

Focused on the deadly and catastrophic problem of stroke that is estimated to cost the healthcare system more than $34BB annually in the US alone

The current addressable market for CGuard™ EPS is estimated to be $1BB with the potential to further expand into the 1.6MM patient population which is diagnosed but not treated

Currently, vascular surgeons treat the majority of patients with carotid artery disease: Focus will be on converting the vascular surgeons to use CGuard™ EPS

Strong and consistent clinical data continues to validate the safety profile of CGuard™ EPS even in a large “all comer” patient population with data indicating sustained benefit out to 3 years

Increasingly more presentations and live clinical cases with CGuard™ EPS are featured at major and regional clinical conferences

Following the sterilizer event in Q1, company made a solid recovery and has returned to normal operations

Increased focus, positive large clinical trials and significant investment in minimally invasive treatment of carotid artery disease is creating a tailwind for CGuard™ EPS

Product pipeline to support continued growth in all geographies, including the United States